Jones & Johnson Emails Reveal FDA Awareness of Tylenol Autism Risk Amid Rising Lawsuits

Internal documents reveal that Johnson & Johnson and the FDA have been aware for years of research suggesting a link between prenatal acetaminophen (Tylenol) use and neurodevelopmental disorders like autism and ADHD, yet the company avoided funding further studies fearing confirmation of this risk. In 2025, President Donald Trump publicly announced government efforts linking acetaminophen use during pregnancy to autism, urging caution, which sparked criticism from major medical groups emphasizing the drug's established safety and the lack of causal proof. The FDA has since begun updating acetaminophen labeling to inform the public of potential risks, though it maintains that acetaminophen remains the only over-the-counter fever treatment approved for pregnant women. This presidential spotlight has led to a surge in lawsuits against Kenvue, the current Tylenol producer, with attorneys reporting increased calls from potential clients alleging harm from the drug. Despite this, companies and some scientists continue to deny a definitive causal link, highlighting the ongoing debate and legal battles surrounding acetaminophen's safety in pregnancy. Public health organizations urge caution in interpreting the data, warning against premature conclusions that could endanger pregnant women needing effective fever and pain relief.